| 17.63 0.24 (1.38%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.82 | 1-year : | 24.32 |
| Resists | First : | 17.82 | Second : | 20.82 |
| Pivot price | 17.27 |
|||
| Supports | First : | 16.84 | Second : | 16.23 |
| MAs | MA(5) : | 17.49 |
MA(20) : | 17.21 |
| MA(100) : | 16.79  |
MA(250) : | 16.09 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 76.9 |
D(3) : | 75.8 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 18.89 | Low : | 12.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TAK ] has closed below upper band by 23.7%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.66 - 17.77 | 17.77 - 17.87 |
| Low: | 17.23 - 17.36 | 17.36 - 17.48 |
| Close: | 17.44 - 17.62 | 17.62 - 17.8 |
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Fri, 14 Aug 2026
Nicola Greenway (TAK) plans sale of 12,980 Takeda ADSs after RSU vesting - Stock Titan
Wed, 12 Aug 2026
Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares of Stock - MarketBeat
Wed, 12 Aug 2026
Takeda Pharmaceutical (NYSE:TAK) Insider Sells $531,519.30 in Stock - MarketBeat
Wed, 12 Aug 2026
Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock - MarketBeat
Wed, 12 Aug 2026
Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $124,436.70 in Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 3,190 (M) |
| Shares Float | 3,160 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 3,820 (K) |
| Shares Short P.Month | 5,370 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.35 |
| Profit Margin | -3.6 % |
| Operating Margin | 16.4 % |
| Return on Assets (ttm) | 2.6 % |
| Return on Equity (ttm) | -2.3 % |
| Qtrly Rev. Growth | 10.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.9 % |
| Operating Cash Flow | 953,630 (M) |
| Levered Free Cash Flow | 541,440 (M) |
| PE Ratio | -53.43 |
| PEG Ratio | 0.3 |
| Price to Book value | 1.22 |
| Price to Sales | 1.21731e+010 |
| Price to Cash Flow | 0.05 |
| Dividend | 0.34 |
| Forward Dividend | 0 |
| Dividend Yield | 1.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|